AbbVie Inc. - notizie pubblicate 394 - letture 16.038
ABBVIE INC.
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis
Immunology r&d news july 12, 2024 abbvie submits regulatory applications to fda and ema for upadacitinib (rinvoq®) in giant cell arteritis open a printable version of this pag ...
ABBVIE INC.
AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer
Corporate news r&d news july 10, 2024 abbvie announces appointment of roopal thakkar, m.d. as executive vice president, research & development and chief scientific officer ...
ABBVIE INC.
Results of Operations and Financial Condition Form 8 K
Abbvie inc. guidance including the impact of acquired ipr&d and milestones expense (unaudited) (in millions, except per share data) quarter ended june 30, 2024 full-year ended ...
ABBVIE INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ABBVIE INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ABBVIE INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ABBVIE INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ABBVIE INC.
AbbVie to Host Second-Quarter 2024 Earnings Conference Call
Corporate news july 02, 2024 abbvie to host second-quarter 2024 earnings conference call open a printable version of this page email the url of this page to a friend north chicago, ...
ABBVIE INC.
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
Corporate news july 01, 2024 robert a. michael assumes role as abbvie chief executive officer open a printable version of this page email the url of this page to a friend as previo ...
ABBVIE INC.
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Oncology r&d news june 28, 2024 abbvie receives positive chmp opinion for epcoritamab (tepkinly®) for the treatment of adults with relapsed/refractory follicular lymphoma open ...
ABBVIE INC.
Annual Report of Employee Stock Purchase/Savings Plan Form 11 K
United states securities and exchange commission washington, d. c. 20549 form 11-k for annual reports of employee stock purchase, savings and similar plans pursuant to section 15(d ...
ABBVIE INC.
AbbVie Acquires Celsius Therapeutics
Immunology r&d news june 27, 2024 abbvie acquires celsius therapeutics open a printable version of this page email the url of this page to a friend celsius' cel383 is a potenti ...
ABBVIE INC.
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
Oncology r&d news june 26, 2024 u.s. food and drug administration grants second approval for epkinly® (epcoritamab-bysp) to treat patients with relapsed or refractory follicul ...
ABBVIE INC.
AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
Corporate news june 20, 2024 abbvie appoints roxanne s. austin as lead independent director of the board of directors open a printable version of this page email the url of this pa ...
ABBVIE INC.
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
Immunology product news june 18, 2024 u.s. fda approves skyrizi® (risankizumab-rzaa) for ulcerative colitis, expanding abbvie's portfolio across inflammatory bowel disease open a ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti